Significant receptor affinities of metabolites and a degradation product of mometasone furoate
- PMID: 15285788
- PMCID: PMC499542
- DOI: 10.1186/1465-9921-5-7
Significant receptor affinities of metabolites and a degradation product of mometasone furoate
Abstract
Mometasone furoate (MF) is a highly potent glucocorticoid used topically to treat inflammation in the lung, nose and on the skin. However, so far no information has been published on the human glucocorticoid receptor activity of the metabolites or degradation products of MF. We have now determined the relative receptor binding affinities of the known metabolite 6beta-OH MF and the degradation product 9,11-epoxy MF to understand their possible contribution to undesirable systemic side effects. In competition experiments with human lung glucocorticoid receptors we have determined the relative receptor affinities (RRA) of these substances with reference to dexamethasone (RRA = 100). We have discovered that 6beta-OH MF and 9,11-epoxy MF display RRAs of 206 +/- 15 and 220 +/- 22, respectively. This level of activity is similar to that of the clinically used inhaled corticosteroid flunisolide (RRA 180 +/- 11). Furthermore we observed that 9,11-epoxy MF is a chemically reactive metabolite. In recovery experiments with human plasma and lung tissue we found a time dependent decrease in extractability of the compound. Hence, we provide data that might contribute to the understanding of the pharmacokinetics as well as the clinical effects of MF.
Figures


Similar articles
-
Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate.Respir Res. 2007 Jul 25;8(1):54. doi: 10.1186/1465-9921-8-54. Respir Res. 2007. PMID: 17650349 Free PMC article.
-
Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate.J Pharm Sci. 2004 May;93(5):1337-50. doi: 10.1002/jps.20049. J Pharm Sci. 2004. PMID: 15067709
-
Characterization of degradation products of mometasone furoate.Pharmazie. 2004 May;59(5):367-73. Pharmazie. 2004. PMID: 15212303
-
Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children.Expert Opin Pharmacother. 2009 Aug;10(12):2009-14. doi: 10.1517/14656560903078428. Expert Opin Pharmacother. 2009. PMID: 19618993 Review.
-
Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy.Clin Ther. 2008 Jan;30(1):1-13. doi: 10.1016/j.clinthera.2008.01.005. Clin Ther. 2008. PMID: 18343239 Review.
Cited by
-
Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate.Respir Res. 2007 Jul 25;8(1):54. doi: 10.1186/1465-9921-8-54. Respir Res. 2007. PMID: 17650349 Free PMC article.
-
Mometasone furoate in the management of asthma: a review.Ther Clin Risk Manag. 2008 Dec;4(6):1201-8. doi: 10.2147/tcrm.s3261. Ther Clin Risk Manag. 2008. PMID: 19337427 Free PMC article.
-
Mometasone Furoate Suppresses PMA-Induced MUC-5AC and MUC-2 Production in Human Airway Epithelial Cells.Tuberc Respir Dis (Seoul). 2017 Jan;80(1):60-68. doi: 10.4046/trd.2017.80.1.60. Epub 2016 Dec 30. Tuberc Respir Dis (Seoul). 2017. PMID: 28119748 Free PMC article.
References
-
- Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs. 2001;61:1325–1350. - PubMed
-
- Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol. 2002;3:47–58. - PubMed
-
- O'Connor B, Bonnaud G, Haahtela T, Luna JM, Querfurt H, Wegener T, Lutsky BN. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol. 2001;86:397–404. - PubMed
-
- Würthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharm Ztg Wiss. 1992;4:161–167.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources